Government of Western Australia
North Metropolitan Health Service
Women and Newborn Health Service

ADULT MEDICATION GUIDELINE	
Phytomenadione (Vitamin K)	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

Medication Class

Drug affecting haemostasis

Presentation

Ampoule: 10 mg/1 mL

Ampoule: 2 mg/0.2 mL

Storage

Store at room temperature, below 25°C. Protect from light.

Dose

Reversing warfarin over-treatment:

Refer to Anticoagulation Medication Chart MR810.11 and discuss with the Haematologist

Prolonged prothrombin time in obstetric cholestasis:

Oral: 10 mg once daily – due to the lack of an oral tablet or capsule, the 10 mg/1 mL and 2 mg/0.2 mL ampoules can be orally administered

IV: 10 mg once weekly

Vitamin K supplementation during pregnancy is no longer routinely recommended to reduce the risk of haemorrhage in neonates with gestational exposure to enzyme-inducing antiseizure drugs (eg carbamazepine); instead ensure the neonate receives intramuscular vitamin K immediately after birth.

Administration

Refer to the Australian Injectable Drugs Handbook

Oral

Can be taken without regard to food. Ampoules may be administered orally (ampoules are shard-proof).

Monitoring

Refer to Anticoagulation Medication Chart MR810.11
Clinical monitoring: New or worsening bruising, epistaxis, bleeding gums, GI bleeding

Pregnancy

1st Trimester: Considered safe to use

2nd Trimester: Considered safe to use

3rd Trimester: Considered safe to use

Breastfeeding

Safe to use

Comments

Phytomenadione (Vitamin K1) 10 mg capsules have been discontinued in Australia from March 2026. No alternative tablet or capsule formulations are currently available.

Phytomenadione (vitamin K1) 2 mg/0.2 mL ampoules (Konakion® MM paediatric) and 10 mg/1 mL ampoules (Konakion® MM) are licensed for oral and intravenous use.

While both ampoule strengths may be administered orally, the Konakion® MM paediatric 2 mg/0.2 mL formulation is preferred when an oral dose is required, as the product packaging includes an oral dispenser to facilitate accurate and safe administration. For instructions on oral administration, see the guideline here: Phytomenadione (Vitamin K) neonatal

As per the WNHS Medication Administration Policy and Procedure all doses of oral liquid medications are only to be measured and administered using an oral/enteral syringe.

Related Policies, Procedures & Guidelines

Warfarin - UKCPA Handbook of Perioperative Medicines

Pre-operative Medication Management

SA Health Intrahepatic Cholestasis of Pregnancy

HDWA Mandatory Policies:

Guidelines for the WA Anticoagulation Medication Chart (WA AMC)

WNHS Clinical Practice Guidelines:

Pre-operative Medication Management

Cholestasis: Intrahepatic cholestasis of pregnancy

Cardiac disease and pregnancy

VTE Prevention and Management

Blood Transfusion Manual (Adults) - Intranet only

WNHS Pharmaceutical and Medicines Management Guidelines:

WNHS.PMM.High Risk Medication Management

Other

Vitamin Mineral Supplementation Post-Bariatric Surgery

References

Australian Medicines Handbook. Vitamin K. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2026 [cited 2026 Mar 26]. Available from: https://amhonline.amh.net.au/

The Royal Women's Hospital. Vitamin K (Phytomenadione). In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2024 [cited 2026 Mar 26]. Available from: https://thewomenspbmg.org.au/

South Australian Maternal & Neonatal Community of Practice. Obstetric Cholestasis. South Australian Perinatal Practice Guidelines [Internet]. 2016 [updated 2021 Aug 11; cited 2026 Mar 26]. Available from: http://www.sahealth.sa.gov.au/

Society of Hospital Pharmacists of Australia. Phytomenadione. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2026 [cited 2026 Mar 26]. Available from: http://aidh.hcn.com.au

Society of Obstetric Medicine of Australia and New Zealand. Intrahepatic Cholestasis of Pregnancy – Diagnosis and Management: A Consensus Statement of the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) [Internet]. [place unknown]: Society of Obstetric Medicine of Australia and New Zealand; 2023 [cited 2026 Mar 27]. Available from: https://www.somanz.org/content/uploads/2023/08/SOMANZ-ICP-Consensus-Statement-1.6.23-Web-Version.pdf

Girling J, Knight CL, Chappell L; Royal College of Obstetricians and Gynaecologists. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43 June 2022. BJOG [Internet]. 2022 Dec

[cited 2026 Mar 27];129(13):1-20. Available from: https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17206

Antiseizure drug use during pregnancy. In: Therapeutic Guidelines. Therapeutic Guidelines Limited; December, 2025. Accessed Apr 1, 2026. https://www.tg.org.au/

Australasian Neonatal Medicines Formulary (ANMF). Vitamin K_1 (Phytomenadione). In: Australasian Neonatal Medicines Formulary [Internet]. Sydney, New South Wales; 2022 [cited 2026 Apr 1]. Available from: www.anmfonline.org

AusDI [Internet]. St Leonards (NSW): Health Communication Network; c2026. Konakion® MM (; [updated 2025 Jan 21; cited 2026 Mar 26]. Available from: Quick Product Search - AusDI

Keywords	Phytomenadione, Vitamin K, Konakion, warfarin reversal, cholestasis, risk reduction, haemorrhage, vit k				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0 – complete review, removal of 10 mg capsules, addition of 2 mg/0.2mL, removal of high risk medicines status, replace statement for *reducing risk of haemorrhage in neonates whose mothers are taking antiepileptic medications* with Therapeutic Guidelines statement, addition of comments section, additional references, links updated				
Date First Issued:	08/2015	Last Reviewed:	27/03/2026	Review Date:	27/03/2031
Endorsed by:	Medicines and Therapeutics Committee			Date:	21/04/2026
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance ☐ Std 2: Partnering with Consumers ☐ Std 3: Preventing and Controlling Healthcare Associated Infection ☒ Std 4: Medication Safety			☐ Std 5: Comprehensive Care ☐ Std 6: Communicating for Safety ☐ Std 7: Blood Management ☐ Std 8: Recognising and Responding to Acute Deterioration	

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2026

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.